Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Company research

BEACON TOPCO, INC.

CIK 2094256Updated Nov 22, 2026

No exchange listing on record for this SEC filer. Coverage is drawn from its filings.

Filing activity

SEC EDGAR
Latest filing

8-K12B · Nov 20, 2026

17 filings on record · 8-K12B, 10-Q, 8-K, SC TO-I/A, SC TO-I, SP 15D2.

Offerings

Registration 333-291359

S-4/A · 2026-04-13 · 0001104659-26-042689

Terms from the governing filing for this registration; not a claim that the offering is open today.

Filing attachments

tm2628797d1_ex99-1.htm · 8-K12B · 2026-11-20

Exhibit 99.1 CLYWEDOG THERAPEUTICS, INC. Condensed Consolidated Financial Statements As of June 30, 2026 and December 31, 2025 and for the Three and Six Months Ended June 30, 2026 and 2025 TABLE OF CONTENTS Condensed Consolidated Financial Statements Condensed Consolidated Balance Sheets as of June 30, 2026 (Unaudited) and December 31, 2025 F-3 Unaudited Condensed Consolidated Statements of Operations …

8-K12B · 2026-11-20 · 0001104659-26-130676

Read attachment ↗
tm2628797d1_ex99-2.htm · 8-K12B · 2026-11-20

Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Introduction On September 29, 2025, Barinthus Biotherapeutics plc, a public limited company organized under the laws of England and Wales (“Barinthus Bio”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among Barinthus Bio, Clywedog Therapeutics Holdings, Inc. (formerly known as Beacon Topco, Inc.), a Delaware corporation and a direct wholly owned subsidiary of Barinthus Bio (“Topco”), Cdo…

8-K12B · 2026-11-20 · 0001104659-26-130676

Read attachment ↗
tm2625953d2_ex99-1.htm · 8-K · 2026-09-24

Exhibit 99.1 FOR IMMEDIATE RELEASE Clywedog Therapeutics Announces Final Results from a Phase 1b Study of Balomenib in Type 2 Diabetes Patients, Showing Glycemic Improvement Sustained for Three Months After a Three-Week Course of Treatment o Placebo-adjusted mean HbA1c reduction of 0.77% at Week 12 (p<0.01) and 0.70% at Week 16 (p<0.05) — three months after the last dose — following only three weeks of balomenib treatment o Statistically signific…

8-K · 2026-09-24 · 0001104659-26-110241

Read attachment ↗
tm2530015d15_ex99-1.htm · S-4/A · 2026-04-13

EX-99.1 5 tm2530015d15_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Consent of Oppenheimer & Co. Inc. Oppenheimer & Co. Inc. (“Oppenheimer”) hereby consents to the inclusion of our opinion letter, dated September 29, 2025, to the Board of Directors (in its capacity as such) of Barinthus Biotherapeutic PLC (“Barinthus Bio”) included as Annex G, and to the references thereto under the captions “Summary - Opinion of Oppenheimer as Financial Advisor of Barinthus Bio,” “The Transactions - Background o…

S-4/A · 2026-04-13 · 0001104659-26-042689

Read attachment ↗
tm2530015d4_ex99-1.htm · S-4/A · 2026-01-27

Exhibit 99.1 Consent of Oppenheimer & Co. Inc. Oppenheimer & Co. Inc. (“Oppenheimer”) hereby consents to the inclusion of our opinion letter, dated September 29, 2025, to the Board of Directors (in its capacity as such) of Barinthus Biotherapeutic PLC (“Barinthus Bio”) included as Annex G, and to the references thereto under the captions “Summary - Opinion of Oppenheimer as Financial Advisor of Barinthus Bio,” “The Transactions - Background of the Transactions”, “The Transactions - Barinthus …

S-4/A · 2026-01-27 · 0001104659-26-007023

Read attachment ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.